Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Dow
Deloitte
Harvard Business School
Citi
Argus Health
Healthtrust
Moodys
Express Scripts

Generated: July 18, 2018

DrugPatentWatch Database Preview

WELLBUTRIN XL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Wellbutrin Xl, and what generic alternatives are available?

Wellbutrin Xl is a drug marketed by Valeant Intl and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in WELLBUTRIN XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Drug patent expirations by year for WELLBUTRIN XL
Synonyms for WELLBUTRIN XL
( inverted question mark)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride
(.+-.)-2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride
(+-)-2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride
(+-)-alpha-tert-Butylamino-3-chloropropiophenone hydrochloride
(+/-)-1-(3-Chlorophenyl)-2- [(1,1-dimethylethyl)amino]- 1-propanone hydrochloride
(+/-)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride
(+/-)-2-(t-butylamino)-3'-chloropropiophenone hydrochloride
1-(3-CHLOROPHENYL)-2-[(1,1-DIMETHYLETHYL)AMINO]-1-PROPANE, MONOHYDROCHLORIDE
1-(3-CHLOROPHENYL)-2-[(1,1-DIMETHYLETHYL)AMINO]-1-PROPANONE HYDROCHLORIDE
1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, hydrochloride, (+-)-
1-Propanone,1-dimethylethyl)amino]-, hydrochloride, (.+-.)-
2-(tert-Butylamino)-1-(3-chlorophenyl)-1-propanone Hydrochloride
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one HCl
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrochloride
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrochloride
2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride
31677-93-7
34841-36-6
4CH-007122
77B937
A820950
AB0012179
AB02273
AB2000567
AC-196
AC1L1XZA
ACM34841366
AK-75760
AKOS015844544
alpha-(tert-Butylamino)-m-chloropropiophenone hydrochloride
AM20060780
Amfebutamon hydrochlorid
Amfebutamon hydrochloride
Amfebutamone (Bupropion) HCl
Amfebutamone hydrochloride
Amfebutamone(Bupropion)
AN-16061
ANW-42367
API0001440
AX8118984
B3649
BC208314
BCP0726000049
BCP9000462
BG0117
Bio-0883
Budeprion
Budeprion XL
Budeprion XL 300
Bupropion (hydrochloride)
Bupropion Hcl
Bupropion hydrochloride
Bupropion hydrochloride (JAN/USP)
Bupropion hydrochloride [USAN:USP:JAN]
Bupropion hydrochloride [USAN:USP]
Bupropion Hydrochloride 1.0 mg/ml in Methanol (as free base)
Bupropion hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Bupropion hydrochloride, >=98% (HPLC), solid
Bupropion Hydrochloride, pharmaceutical secondary standard; traceable to USP
Bupropion hydrochloride, United States Pharmacopeia (USP) Reference Standard
Bupropion hydrocloride
BW 323
BW-323
BW-323U66
CAS-31677-93-7
CCG-100911
CCG-39085
CHEBI:3220
CHEMBL1698
CPD000058423
CPI-300
CS-2503
CTK8B3357
D00817
DSSTox_CID_24561
DSSTox_GSID_44561
DSSTox_RID_80314
DTXSID6044561
EINECS 250-759-9
EINECS 252-243-9
EU-0100166
Forfivo XL
FT-0081218
FT-0623288
HEYVINCGKDONRU-UHFFFAOYSA-N
HMS1568B20
HMS1922F09
HSDB 6988
HY-B0403A
I06-0019
I06-19
J10311
Jsp005899
KB-224632
KS-00000XL2
KS-1034
LP00166
LS-125089
M-5146
m-Chloro-alpha-tert-butylaminopropionphenone hydrochloride
m-Chloro-alpha-tert-butylaminopropiophenone hydrochloride
MFCD00055209
MLS000069376
MLS001401370
MLS002320678
NC00161
NCGC00015122-11
NCGC00016807-01
NCGC00093650-01
NCGC00093650-02
NCGC00093650-03
NCGC00093650-04
NCGC00093650-05
NCGC00180895-01
NCGC00180895-02
NCGC00255927-01
NCGC00260851-01
NSC 315851
NSC-315851
NSC-758686
NSC315851
NSC758686
OR147496
Pharmakon1600-01504174
Prestwick_668
Propiophenone, 2-(tert-butylamino)-3'-chloro-, hydrochloride, (+-)-
Propiophenone, hydrochloride, (.+-.)-
PubChem20752
Quomem
S2452
SAM001246723
SC-12179
SCHEMBL41602
SMR000058423
SMR001338824
SPECTRUM1504174
ST24027672
TC-010273
Tox21_110621
Tox21_110621_1
Tox21_301844
Tox21_500166
V2047
Voxra
Wellbutrin
Wellbutrin (TN)
Wellbutrin Retard
Wellbutrin SR
Wellbutrin XR
Wellbutrin;Zyban;Voxra;Budeprion;Aplenzin;Bupropion
Zyban
Zyban (pharmaceutical)
Zyban (TN)

US Patents and Regulatory Information for WELLBUTRIN XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-001 Aug 28, 2003 AB3 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Intl WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-002 Aug 28, 2003 AB3 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for WELLBUTRIN XL
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe ➤ Try a Free Trial

Non-Orange Book US Patents for WELLBUTRIN XL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,327 Delayed release coated tablet of bupropion hydrochloride ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Cipla
Teva
UBS
Baxter
Argus Health
Cerilliant
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.